Patient Scenario 2: A 65-Year-Old Man With Metastatic Hormone-Sensitive Prostate Cancer

Centering focus on a second clinical scenario of metastatic hormone-sensitive prostate cancer, key opinion leaders identify treatment options based on variations in presentation.

Related Videos
Experts on colorectal cancer
Experts on multiple myeloma
Experts on multiple myeloma
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Experts on colorectal cancer
Arvind Dasari, MD, MS, an expert on colorectal cancer
Experts on multiple myeloma
Expert on prostate cancer
Experts on multiple myeloma
Related Content